PMID- 32534870
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20220510
IS  - 1579-2129 (Electronic)
IS  - 0300-2896 (Linking)
VI  - 58
IP  - 4
DP  - 2022 Apr
TI  - Diagnosis of Tuberculous Infection in Immunosuppressed Patients and/or Candidates 
      for Biologics Using a Combination of 2 IGRA Tests: T-SPOT.TB/QuantiFERON TB Gold 
      In-Tube vs. T-SPOT.TB/QuantiFERON TB Gold Plus.
PG  - 305-310
LID - S0300-2896(20)30128-9 [pii]
LID - 10.1016/j.arbres.2020.04.011 [doi]
AB  - INTRODUCTION: The diagnosis of latent tuberculous infection (LTI) by IGRA 
      continues to generate debate. Experience in the simultaneous use of 2 IGRA tests 
      is scant. The aim of this study was to compare the results of 2 versions of 
      QuantiFERON-TB Gold (In-Tube/Plus) with those of T-SPOT.TB, and to analyse the 
      effectiveness of a dual strategy (T-SPOT.TB + QTF) for the diagnosis of LTI in an 
      immunosuppressed population. METHODS: We conducted a prospective study (May 
      2015-June 2017) that included 2,999 immunosuppressed patients and/or candidates 
      for biologics, in whom 2 simultaneous IGRA tests were performed: Group 1 (1535 
      patients): T-SPOT.TB + QuantiFERON-TB Gold-In-Tube (QTF-GIT); Group 2 (1464 
      patients): T-SPOT.TB + QuantiFERON-TB Gold Plus (QTF-Plus). RESULTS: The 
      concordance between QTF-GIT and T-SPOT.TB was 83.19% (kappa=0.532). The percentage of 
      positive, negative, and indeterminate results were, respectively: 14.33% vs. 
      17.06%; 82.41% vs. 74.46%; and 3.25% vs. 8.46%. The concordance between QTF-Plus 
      and T-SPOT.TB was 87.56% (kappa=0.609). The percentage of positive, negative, and 
      indeterminate results were, respectively: 15.02% vs. 15.36%; 82.92% vs. 79.37%; 
      and 2.04% vs. 5.25%. Discrepancies between T-SPOT.TB and QTF-Plus were 12.43%, 
      suggesting that 103 patients were positive and another 79 were negative due 
      exclusively to 1 of the 2 IGRAs. CONCLUSIONS: Greater concordance was found 
      between QTF-Plus and T-SPOT.TB than between QTF-GIT and T-SPOT.TB. However, we 
      believe that the proportion of discrepancies between T-SPOT.TB and QTF-Plus is 
      sufficiently important from a clinical point of view to justify the simultaneous 
      use of 2 IGRA in this specific patient group.
CI  - Copyright (c) 2020 SEPAR. Publicado por Elsevier Espana, S.L.U. All rights 
      reserved.
FAU - Fernandez-Blazquez, Ana
AU  - Fernandez-Blazquez A
AD  - Unidad de Referencia Regional de Micobacterias, Servicio de Microbiologia, 
      Hospital Universitario Central de Asturias, Espana; Instituto de Investigacion 
      Sanitaria del Principado de Asturias (ISPA), Espana. Electronic address: 
      anafdezblazquez@hotmail.com.
FAU - Arguelles Menendez, Pablo
AU  - Arguelles Menendez P
AD  - Unidad de Referencia Regional de Micobacterias, Servicio de Microbiologia, 
      Hospital Universitario Central de Asturias, Espana.
FAU - Sabater-Cabrera, Christian
AU  - Sabater-Cabrera C
AD  - Unidad de Referencia Regional de Micobacterias, Servicio de Microbiologia, 
      Hospital Universitario Central de Asturias, Espana; Instituto de Investigacion 
      Sanitaria del Principado de Asturias (ISPA), Espana.
FAU - Garcia-Garcia, Jose-Maria
AU  - Garcia-Garcia JM
AD  - Servicio de Neumologia, Hospital Universitario San Agustin, Asturias, Espana.
FAU - Asensi Alvarez, Victor
AU  - Asensi Alvarez V
AD  - Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital 
      Universitario Central de Asturias, Facultad de Medicina, Universidad de Oviedo, 
      Espana.
FAU - Palacios Gutierrez, Juan Jose
AU  - Palacios Gutierrez JJ
AD  - Unidad de Referencia Regional de Micobacterias, Servicio de Microbiologia, 
      Hospital Universitario Central de Asturias, Espana; Instituto de Investigacion 
      Sanitaria del Principado de Asturias (ISPA), Espana.
CN  - en representacion de la Red de Laboratorios de Microbiologia del SESPA
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Diagnostico de la infeccion tuberculosa en pacientes inmunodeprimidos y/o 
      candidatos a terapias biologicas mediante el uso combinado de dos pruebas IGRA: 
      T-SPOT.TB/QuantiFERON TB Gold In-Tube vs. T-SPOT.TB/QuantiFERON TB Gold Plus.
DEP - 20200610
PL  - Spain
TA  - Arch Bronconeumol
JT  - Archivos de bronconeumologia
JID - 0354720
RN  - 0 (Biological Products)
SB  - IM
MH  - *Biological Products
MH  - Humans
MH  - Interferon-gamma Release Tests
MH  - *Latent Tuberculosis/diagnosis
MH  - Prospective Studies
MH  - Tuberculin Test/methods
MH  - *Tuberculosis/diagnosis
OTO - NOTNLM
OT  - Biological immunomodulators
OT  - IGRA
OT  - IGRAs
OT  - Infeccion tuberculosa latente
OT  - Inmunomoduladores biologicos
OT  - Latent tuberculous infection
OT  - QuantiFERON
OT  - T-SPOT.TB
EDAT- 2020/06/15 06:00
MHDA- 2022/05/11 06:00
CRDT- 2020/06/15 06:00
PHST- 2019/10/09 00:00 [received]
PHST- 2020/03/05 00:00 [revised]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
PHST- 2020/06/15 06:00 [entrez]
AID - S0300-2896(20)30128-9 [pii]
AID - 10.1016/j.arbres.2020.04.011 [doi]
PST - ppublish
SO  - Arch Bronconeumol. 2022 Apr;58(4):305-310. doi: 10.1016/j.arbres.2020.04.011. 
      Epub 2020 Jun 10.